Vasanthavada Madhav 4

What Happened
Vasanthavada Madhav, Chief Commercial Officer of Abeona Therapeutics (ABEO), reported two transactions: a grant of 76,621 restricted shares on 2026-01-20 (acquired at $0.00) and an open-market sale of 12,610 shares on 2026-01-22 at a weighted average price of $5.29, generating proceeds of about $66,658. The grant is a restricted stock award (not a purchase), while the sale is a disposition — here disclosed as having been made to cover tax obligations tied to the vesting award.

Key Details

• Grant: 76,621 restricted shares granted on 2026-01-20 at $0.00 (total reported value $0). Vesting: one-third on each of Jan 20, 2027; Jan 20, 2028; Jan 20, 2029 (Footnote F1).
• Sale: 12,610 shares sold on 2026-01-22, weighted average price $5.29, proceeds ~$66,658 (Footnote F3: sale prices ranged $5.28–$5.35).
• Reason for sale: reported as tax-withholding sale to cover tax obligations related to the restricted stock vesting (Footnote F2).
• Shares owned after transaction: not stated in the provided filing.
• Filing: Form 4 filed 2026-01-26; filing appears timely relative to the reported transaction dates.

Context
This filing shows a common executive equity event: a grant of restricted stock combined with a small, routine sale to cover taxes. Grants (awards) are not purchases indicating market sentiment; the sale here is explicitly tax-related rather than a discretionary investment choice.